- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02658422
Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions
May 5, 2017 updated by: GlaxoSmithKline
An Open-label Balanced, Randomised, Single Dose, Two-way Crossover Study to Determine the Bioequivalence of GW483100 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) Relative to Reference Montelukast Sodium 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) in Healthy Male and Female Volunteers Under Fasting Conditions
This study is conducted to determine whether the test product (GW483100 10 mg containing montelukast sodium equivalent to 10 mg of montelukast) is bioequivalent to the reference montelukast sodium 10 mg tablets (innovator product) in healthy adult volunteers under fasting conditions.
This is an open-label, balanced, randomized, single dose, two-way crossover study, enrolling 32 healthy human subjects to ensure at least 28 subjects complete the study.
Each subject enrolled will participate in two treatment periods separated by a washout period of at least 7 days and no more than 14 days between dosing occasions.
Total duration in the study for each subject will be approximately 7 weeks from screening to the subject's last visit.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Telangana, India, 500 013
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- Healthy, non smoker, as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 19 - 24.9 kg/square meter (m^2) (inclusive)
- Healthy male or female subjects: MALES: Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until 24 hours after the last dose of study medication. a.) Vasectomy with documentation of azoospermia. b.) Male condom plus partner use of one of the contraceptive following options: contraceptive subdermal implant; intrauterine device or intrauterine system; oral contraceptive, either combined or progestogen alone; injectable progestogen; contraceptive vaginal ring; and percutaneous contraceptive patches. FEMALES: Eligible to participate, if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies: a.) Non-reproductive potential defined as: Pre-menopausal females with one of the following: documented tubal ligation, documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion, hysterectomy, Documented Bilateral Oophorectomy Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. b.) Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication and until 24 hours after the last dose of study medication and completion of the follow-up visit.
- Capable of giving signed informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the consent form and in the protocol.
Exclusion Criteria:
- Alanine aminotransferase (ALT) and bilirubin >1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Corrected QT (QTc) > 450 millisecond (msec) NOTES: The QTc is the QT interval corrected for heart rate according to Bazett's formula (QTcB), Fridericia's formula (QTcF), and/or another method, machine-read or manually over-read; The specific formula that will be used to determine eligibility and discontinuation for an individual subject should be determined prior to initiation of the study. In other words, several different formulae cannot be used to calculate the QTc for an individual subject and then the lowest QTc value used to include or discontinue the subject from the trial; For purposes of data analysis, QTcB, QTcF, another QT correction formula, or a composite of available values of QTc will be used as specified in the Reporting and Analysis Plan (RAP).
- No concomitant medications should be taken by the subject while participating in the study.
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (~240 milliliter [mL]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
- A positive pre-study drug/alcohol screen.
- A positive test for Human Immunodeficiency Virus (HIV) antibody.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 90 days.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.
- Any symptoms with a systolic BP <95 millimeter of mercury (mmHg).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence A-B (Test Montelukast then Reference Montelukast)
Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
|
Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
|
Experimental: Sequence B-A (Reference Montelukast then Test Montelukast)
Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
|
Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the concentration versus time from time zero to infinity (AUC(0 ∞)) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
AUC from time zero to last time point with measurable concentration (AUC(0-t)) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
Maximum observed concentration (Cmax) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of occurrence of Cmax (tmax) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Percentage of AUC(0-∞) obtained by extrapolation (%AUCex) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Terminal phase half-life (t½) for montelukast in relevant treatments
Time Frame: Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Blood samples will be withdrawn on Day 1 and Day 2, and concentrations of montelukast will be determined in plasma samples.
Plasma montelukast concentration-time will be analyzed by non-compartmental method and the PK parameters will be derived.
|
Samples will be collected at Pre-dose, 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post-dose in each treatment period.
|
Blood pressure (BP) as a measure of safety and tolerability
Time Frame: 3 days in each treatment period (assessed up to 3 weeks)
|
Systolic and diastolic BP will be measured in supine position after 5 minutes rest.
|
3 days in each treatment period (assessed up to 3 weeks)
|
Pulse rate measurements as a measure of safety and tolerability
Time Frame: 3 days in each treatment period (assessed up to 3 weeks)
|
Pulse rate measurements will be measured in supine position after 5 minutes rest.
|
3 days in each treatment period (assessed up to 3 weeks)
|
Number of participants with adverse events (AEs)
Time Frame: Up to 7 weeks
|
AEs will be collected from the start of study treatment until the subject's last visit.
|
Up to 7 weeks
|
Composite of hematology parameters as a measure of safety
Time Frame: 1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
|
Composite of clinical chemistry parameters as a measure of safety
Time Frame: 1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
|
Composite of urinalysis parameters as a measure of safety
Time Frame: 1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
1 day in Treatment Period 1 and 2 days in Treatment Period 2 (assessed up to 3 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 18, 2015
Primary Completion (Actual)
September 21, 2015
Study Completion (Actual)
September 21, 2015
Study Registration Dates
First Submitted
July 6, 2015
First Submitted That Met QC Criteria
January 14, 2016
First Posted (Estimate)
January 18, 2016
Study Record Updates
Last Update Posted (Actual)
May 9, 2017
Last Update Submitted That Met QC Criteria
May 5, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Otorhinolaryngologic Diseases
- Nose Diseases
- Rhinitis
- Respiration Disorders
- Respiratory Tract Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Leukotriene Antagonists
- Hormone Antagonists
- Cytochrome P-450 CYP1A2 Inducers
- Cytochrome P-450 Enzyme Inducers
- Montelukast
Other Study ID Numbers
- 201681
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Disorders
-
LmecaRecruitingOther Specified Respiratory DisordersKorea, Republic of
-
Centro Universitário Augusto MottaUniversidade Federal do Rio de JaneiroCompletedRespiratory Failure | Respiratory DisordersBrazil
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
Mustafa Kemal UniversityThe Scientific and Technological Research Council of TurkeyCompletedMood Disorders | Physical Inactivity | Respiratory Function ImpairedTurkey
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedRespiratory Disorders
-
GlaxoSmithKlineCompletedRespiratory Disorders
-
Hollister IncorporatedTerminatedRespiratory Failure | Ventilatory Depression | Respiratory DepressionUnited States
-
RespireRxDuke UniversityUnknownOpiate Induced Respiratory DepressionUnited States
Clinical Trials on Test Montelukast
-
GlaxoSmithKlineCompleted
-
Indiana UniversityCompleted
-
Chinese University of Hong KongUniversity of Sydney; Chongqing Medical University; Hong Kong University of Science... and other collaboratorsNot yet recruitingAtherosclerosis, CoronaryHong Kong
-
Kecioren Education and Training HospitalCompletedAsthma | Acute AsthmaTurkey
-
Menarini International Operations Luxembourg SACompletedAsthma | Seasonal Allergic RhinoconjunctivitisPoland, Romania, Germany, Italy, Czechia, Latvia, Croatia, Slovakia
-
Organon and CoCompleted
-
Medical University of LodzUnknownSeasonal Allergic RhinitisPoland
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Kecioren Education and Training HospitalCompletedAcute Asthma | Acute Wheezy BronchitisTurkey
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting